Presenters highlighted early work that supports the push for a national, systematic effort to elucidate progression from precancerous states to clinical malignancy.
The company is in the beginning stages of product development, but is confident that it has a product that will be successful in the early diagnostics market.
The researchers said the technique could be used to identify biomarkers specific to cancer or bacterial infection that are too small to detect by other methods.
The study showed that introducing a synthetic molecule into the blood of mice could force cancer cells, but not normal cells, to express a detectable biomarker.
NEW YORK (GenomeWeb News) – Fluidigm and Olink Bioscience today announced a co-marketing deal that combines each other's technologies to enable the interrogation of 96 samples across 92 proteins in one run from one microliter of sample in less than one day.
NEW YORK (GenomeWeb News) – Nuclea Biotechnologies and the College of Nanoscale Science & Engineering (CNSE) of the State University of New York on Thursday announced a $1 million research partnership to develop and commercialize a high-throughput nanochip to analyze biomarkers associated wit
NEW YORK (GenomeWeb News) – The Centre of Excellence for the Prevention of Organ Failure (PROOF) and MRM Proteomics announced today that they will partner on proteomic-based diagnostic tests for patients with chronic organ diseases.
